Statins: Balancing benefits efficacy and safety

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 5, 2002, Pages 469-477

  Clearfield, Michael B ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Coronary heart disease; Low density lipoprotein cholesterol; Statins

Indexed keywords

ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; CYTOCHROME P450; FELODIPINE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIDOCAINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MIDAZOLAM; NEFAZODONE; NIFEDIPINE; PITAVASTATIN; PLACEBO; PRAVASTATIN; PYRROLE DERIVATIVE; QUINIDINE; ROSUVASTATIN; SIMVASTATIN; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL;

CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG UTILIZATION; EDUCATION PROGRAM; FEMALE; HEADACHE; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MALE; MORBIDITY; MORTALITY; MYALGIA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; PROSPECTIVE STUDY; RASH; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; TREATMENT PLANNING; UNITED STATES; VITAMIN SUPPLEMENTATION;

CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0036098135     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.5.469     Document Type: Review

References (44)

1. 2001 Heart and Stroke Statistical Update
2. Epidemiology of coronary heart disease: The Framingham study
3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
4. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
9. Cholesterol lowering and total mortality
10. Cholesterol lowering with statin drugs, risk of stroke and total mortality. An overview of randomized trials
11. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
12. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
13. Evaluation and Treatment of High Blood Cholesterol in Adults
14. Choosing drug therapy for patients with hyperlipidemia
15. Drug therapy: Drug treatment of lipid disorders
16. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
17. The MRC/BHF Heart Protection Study: Preliminary results
18. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
19. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
20. Long-term effects of pravastatin on plasma concentration of C-reactive protein
21. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
22. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
23. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease
24. Clinically relevant differences between the statins: Implications for therapeutic selection
25. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment
26. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease
27. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
28. The West of Scotland Coronary Prevention Study: Economic benefit analysis of primary prevention with pravastatin
29. Five-hundred life-saving interventions and their cost-effectiveness
30. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults
31. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: Projected impact on the size, sex and age distribution of the treatment-eligible population
32. Effectiveness of antihypertensive drug management in clinical practice
33. The essence of effective treatment and compliance is simplicity
34. Choice of lipid-lowering drugs
35. Comparative tolerability of the HMG-CoA reductase inhibitors
36. Withdrawal of cerivastatin from the world market
37. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
38. New insights into the pharmacodynamic and pharmacokinetic properties of statins
39. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
40. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
41. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with Type IIa or IIb hypercholesterolemia
42. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator controlled trial versus atorvastatin
43. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesteroleamic patients: A randomized, double-blind study
44. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus pravastatin and simvastatin